B/F/TAF + Placebo to match DTG + Placebo to match F/TDF + DTG + F/TDF + Placebo to match B/F/TAF
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HIV-1/HBV Co-Infection
Conditions
HIV-1/HBV Co-Infection
Trial Timeline
May 30, 2018 → Mar 7, 2024
NCT ID
NCT03547908About B/F/TAF + Placebo to match DTG + Placebo to match F/TDF + DTG + F/TDF + Placebo to match B/F/TAF
B/F/TAF + Placebo to match DTG + Placebo to match F/TDF + DTG + F/TDF + Placebo to match B/F/TAF is a phase 3 stage product being developed by Gilead Sciences for HIV-1/HBV Co-Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03547908. Target conditions include HIV-1/HBV Co-Infection.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03547908 | Phase 3 | Completed |